SOURCES SOUGHT
65 -- Zanamivir for Inhalation
- Notice Date
- 1/18/2018
- Notice Type
- Sources Sought
- NAICS
- 325412
— Pharmaceutical Preparation Manufacturing
- Contracting Office
- Defense Logistics Agency, DLA Acquisition Locations, DLA Land and Maritime - Philadelphia Detachment, 700 Robbins Avenue, Philadelphia, Pennsylvania, 19111-5096, United States
- ZIP Code
- 19111-5096
- Solicitation Number
- SPE2DP-18-R-2035
- Point of Contact
- Amanda Doherty, Phone: 215 737 9508
- E-Mail Address
-
Amanda.Doherty@dla.mil
(Amanda.Doherty@dla.mil)
- Small Business Set-Aside
- N/A
- Description
- SPE2DP-18-R-2035 Sources Sought Notice for Zanamivir for Inhalation The Defense Logistics Agency (DLA) Troop Support is seeking sources capable of providing Zanamivir for Inhalation. DLA Troop Support is contemplating awarding a requirements contract with a one-year base period for Zanamivir for Inhalation 5MG Diskhaler 20 Count. The estimated quantity be ordered is 335,000 EA. These quantities may increase or decrease as quantities change. Must have FDA approval to sell Zanamivir for Inhalation before award of the contract. If your firm currently manufactures or distributes Zanamivir for Inhalation, please provide the following information: •a. Place of manufacture •b. Estimated annual capacity •c. FDA registration •d. Product name and description, including description of any special features •e. Current unit sale price •f. Estimated inventory level and storage requirements •g. Shelf life (months) *** NEW PRODUCTS UNDER DEVELOPMENT*** For products under development, describe the current stage of development and whether or not the product has undergone independent laboratory testing or FDA testing/trials, etc. Firms and organizations that currently develop or manufacture Zanamivir for Inhalation or firms that have the technological, pharmaceutical, or manufacturing capabilities under development are invited to submit information to DLA Troop Support. Data obtained from this Request for Information (RFI) will be used by DLA Troop Support in making recommendations and decisions on the development of an appropriate planning and procurement strategy for Zanamivir for Inhalation. All information submitted shall remain with the U.S. Government and will not be returned. It will be kept confidential as allowed by relevant Federal law and will be eligible for additional special protections under the conditions of the Protected Critical Infrastructure Information (PCII) Program outlined in the Critical Infrastructure Act of 2002. This RFI does not commit the U.S. Government to issue a solicitation, make an award, or pay any costs associated with responding to this announcement. Your response to this RFI may be submitted electronically in PDF format and emailed Amanda.Doherty@dla.mil.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/notices/ee19a70e4990ad3ea0b5cae1f062f516)
- Record
- SN04793217-W 20180120/180118231322-ee19a70e4990ad3ea0b5cae1f062f516 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |